Menu

Logos of Novo Nordisk and Eli Lilly

Provider groups have sent letters to the Health Resources and Services Administration, asking the federal regulator to halt Novo Nordisk's and Eli Lilly's new in-house pharmacy 340B claims data reporting requirements.

Provider Groups Oppose Lilly, Novo 340B In-House Pharmacy Data Policies in New Letters

March 12, 2026 Luke Zarzecki, National Correspondent 340B Report Views

Multiple 340B provider groups are pushing back against Novo Nordisk and Eli Lilly’s in-house pharmacy 340B claims data reporting requirements, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Luke Zarzecki

E&C Chair Reintroduces House Bill to Study Value-Based Purchasing Arrangements’ Effect on 340B

Hospital, Physician Groups Among Witnesses for E&C Hearing Next Week on Providers’ Role in Health Care Costs